Subscribe

Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?
Europe
Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?
The tech is being used to crunch thousands of documents in billion-dollar mediations and emerging as a valuable party at the table, finds Muireann Bolger.   23 October 2025
Why AI is changing the patent rules faster than anyone can keep up
Americas
Why AI is changing the patent rules faster than anyone can keep up
A panel of experts at LSPN shared how AI is forcing companies to rethink everything from obviousness arguments to the choice between patents and trade secrets, and why the claims filed today may be invalid tomorrow.   23 October 2025
The hidden code in life sciences deals
Americas
The hidden code in life sciences deals
As IP plays a more important role in corporate valuations, acquirers are discovering that the biggest risks in life sciences deals aren’t always in the patents—they’re in the code, the algorithms, and the data. A panel at LSPN North America Fall shared why traditional due diligence is no longer enough.   23 October 2025
Americas
LSPN panel unpacks critical IP risks in deal-making
Experts at LSPN North America Fall explore the often-overlooked factors that can make or break transactions, from employee retention strategies to cross-border patent standards.   23 October 2025
Americas
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, explain Daniel Muino and Charles Provine from Morrison Foerster.   23 October 2025
Americas
Less is more: patent lawyers flip the script after Amgen
The Supreme Court’s 2023 Amgen ruling turned patent strategy upside down. Now lawyers are rethinking everything they thought they knew about protecting inventions. Marisa Woutersen reports from LSPN North America–Fall.   22 October 2025
Biotechnology
‘Doing more with less’: In-house counsel on budgets and strategy
Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.   22 October 2025
Americas
End of the ‘Death Squad’? Squires puts PTAB on trial
Just weeks into his tenure, USPTO director John Squires is blitzing US patent policy by taking control of how and when patent challenges can be brought, with proposed rules that could sharply limit repeat and parallel filings. Sarah Speight gauges reaction.   22 October 2025
Americas
Data and delivery: Inside AI's inventorship dilemma
Isomorphic Labs' head of IP shares why the first wave of AI-driven drug development stumbled, how data became pharma's most valuable currency, and why inventorship questions could make or break billion-dollar deals in machine learning.   21 October 2025
Careers
Weil continues expansion with top trade secrets litigator
Hire brings trade secrets and AI litigation expertise from Cooley as firm adds 14th US litigation partner this year.   21 October 2025